The agency recently delivered a webinar in which the roadmap for development of a new IT system was outlined. The MHRA is developing a new IT system – the working title of which is currently “RMS”. The aim of the project is to support internal and external interactions with the agency and processing of applications.
Timeline for development
It is expected that the first release of this will occur by the end of 2023. Following a tender process that began in 2021, work on the project formally began on 01 July 2022. In the Discovery phase, research with internal and external end-users on their needs was collected and future workshops and surveys are planned to ensure user needs are met as the system is developed.
Agile delivery model
An agile delivery model is planned, with delivery of the first release scheduled to occur by the end of the year. This will be a “ minimum viable product” (MVP), which, while not having all features enabled or operational, can be used to assess how it meets most user requirements. It is anticipated that the “agile delivery model” will enable user feedback to drive continuous improvement of the system.
Focus on Medicines Regulatory Lifecycle
The first release will be focused on Medicines Regulatory Lifecycle – eg submissions related to product licensing such as marketing authorisations or post-approval variations and Process Licensing – eg wholesale dealer applications.
Subsequent releases will incorporate wider elements, for example:
-
Import notifications
-
Advertising
-
Payment of annual service fees
-
Submissions of enquiries
Points not yet defined and areas for improvement
Points that are not yet defined are, for example:
-
Precise timelines for delivery of the MVP and subsequent iterations
-
The length of any transition period with legacy systems/databases
-
What information will be archived from current systems/databases
The ease of submitting applications and transparency of the timelines and current status are key areas where improvements would bring tangible benefits to both applicants and the agency.
As the MHRA seeks to develop closer ties with other global agencies following Brexit, another key area for the project to consider is whether the new system can better facilitate concurrent applications within the scope of, for example, Project Orbis or the Access Consortium.
Conclusion
In summary, the MHRA is in the process of developing a new IT system that aims to support internal and external interactions with the agency and processing of applications. The first release is expected to occur by the end of 2023, with subsequent releases incorporating additional elements. The agile delivery model will enable user feedback to drive continuous improvement of the system, and there are key areas for improvement that the project will need to address.
Navigate Regulatory Complexity with Confidence
Navigate complex regulatory landscapes with expert guidance across pharmaceuticals, medical devices, and IVD.
Read more订阅生命科学领域的最新动态
专家观点直达您的收件箱——选择您的兴趣。
绝无垃圾邮件。随时取消订阅。
